Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, deferasirox (Exjade®) cannot be endorsed for use within NHS Wales for the treatment of chronic iron overload requiring chelation therapy, when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older. |
||
|
||
Medicine details |
||
| Medicine name | deferasirox (Exjade®) | |
| Formulation | 125 mg, 250 mg and 500 mg dispersible tablet | |
| Reference number | 1621 | |
| Indication | Treatment of chronic iron overload requiring chelation therapy, when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/07/2013 | |